An Adaptive Phase 2 Study of Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Tipifarnib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Kura Oncology
- 11 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 11 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Feb 2018.
- 10 Jun 2017 Biomarkers information updated